Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02638701 · ClinicalTrials.gov registry record · Phase 1

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

A Phase 1 study of Stroke and Vasculitis, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT02638701 is a Phase 1 study of Stroke and Vasculitis that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 8 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02638701, a Phase 1 study of Stroke and Vasculitis, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms

Interventions

  • DRUG Infliximab

Study Locations (1)

California

  • UCSF Medical Center - San Francisco

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-10-01
Est. Completion 2027-12
Phase Phase 1

What the Registry Record Tells You About NCT02638701

The ClinicalTrials.gov registry entry for NCT02638701 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Infliximab is the first listed.

NCT02638701 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02638701 about?

NCT02638701 is a clinical study titled "Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms". Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medic...

What is the current status of trial NCT02638701?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-10-01. Estimated completion is 2027-12.

What conditions does trial NCT02638701 study?

This clinical trial studies the following conditions: Stroke, Vasculitis, Aneurysm, Tumor Necrosis Factor-alpha.

What interventions are being tested in trial NCT02638701?

The interventions under investigation include: Infliximab (DRUG).

Who is sponsoring clinical trial NCT02638701?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02638701 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.